CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Tecentriq & Avastin Non-Squamous Non-Small Cell Lung Cancer - Details

Project Number pCODR 10155
Brand Name Tecentriq & Avastin
Generic Name Atezolizumab & Bevacizumab
Strength 1200 mg/20 mL (60 mg/mL) vial & 100 mg/4 mL (25 mg/mL) and 400mg/16mL (25 mg/mL) vials
Tumour Type Lung
Indication Non-Squamous Non-Small Cell Lung Cancer
Funding Request For the treatment of metastatic EGFR and/or ALK positive non-squamous non-small cell lung cancer in patients who have progressed on treatment with targeted therapies. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should be continued until disease progression or unacceptable toxicity.
Review Status Notification to Implement Issued
Pre Noc Submission No
NOC Date May 24, 2019
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date November 18, 2019
Submission Deemed Complete December 2, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ December 2, 2019
Check-point meeting January 27, 2020
pERC Meeting April 16, 2020
Initial Recommendation Issued April 30, 2020
Feedback Deadline ‡ May 14, 2020
pERC Reconsideration Meeting June 18, 2020
Final Recommendation Issued July 3, 2020
Notification to Implement Issued July 20, 2020

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.